Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Lung Neoplasms 2Recurrence 1Non-Small Cell Lung Cancer ALK-positive 1Neoplasm Metastasis 1Meningeal Carcinomatosis 1Glioma 1Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1Brain Neoplasms 1Astrocytoma 1Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer 1Advanced Non-Small Cell Lung Cancer 1ALK Positive Non-small Cell Lung Cancer 1

Interventions

Magnetic Resonance Spectroscopy 24Temozolomide 20Specimen Handling 13Radiotherapy 12Biopsy 9X-Rays 8Radiation 7trametinib 6Phantoms, Imaging 6Nuclear Medicine Department, Hospital 6Bevacizumab 6larotrectinib 4erdafitinib 4dabrafenib 4abemaciclib 4Cyclophosphamide 4ulixertinib 3palbociclib 3olaparib 3Surgical Procedures, Operative 3Nivolumab 3tipifarnib 2tazemetostat 2selpercatinib 2pembrolizumab 2mirdametinib 2lutetium Lu 177 dotatate 2ivosidenib 2fluorodopa F 18 2fludarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioma × lorlatinib × 90 days × Clear all
NCT06333899 2026-03-12

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

Nationwide Children's Hospital

Phase EARLY_PHASE1 Recruiting
15 enrolled
CNS

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡